Alvogen’s Taiwanese subsidiary Lotus has confirmed a cross-investment partnership with Fuji that will strengthen the firms’ commercial platform in Japan and other key Asian pharmaceutical markets.
Alvogen’s Taiwanese subsidiary Lotus Pharmaceuticals has entered into capital and business collaboration agreements with Fuji Pharma in Japan. Under the terms of the deal, Fuji acquires a 2.0% stake in Lotus for approximately US$20 million, while Lotus acquires a 3.9% stake in Fuji for an equal sum.
In a joint press release, the companies stated that the transaction “is designed to further strengthen Lotus and Fuji’s commercial...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.
